Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Scientific Reports
|
October 7, 2016
A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms
Alan M Jones, Isaac M Westwood, James D Osborne, et al.
Cancer Research
|
March 3, 2007
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors
Swee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Journal of Medicinal Chemistry
|
February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease
Giampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Cancer Research
|
January 4, 2019
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Swee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Health Physics
|
August 2, 2012
Electron paramagnetic resonance dosimetry for a large-scale radiation incident
Harold M Swartz, Ann Barry Flood, Benjamin B Williams, et al.
Oncotarget
|
August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Molecular Cancer Therapeutics
|
April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Journal of Medicinal Chemistry
|
November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing
John C Reader, Thomas P Matthews, Suki Klair, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Scientific Reports
|
October 7, 2016
A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms
Alan M Jones, Isaac M Westwood, James D Osborne, et al.
Cancer Research
|
March 3, 2007
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors
Swee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Journal of Medicinal Chemistry
|
February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease
Giampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Cancer Research
|
January 4, 2019
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Swee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Health Physics
|
August 2, 2012
Electron paramagnetic resonance dosimetry for a large-scale radiation incident
Harold M Swartz, Ann Barry Flood, Benjamin B Williams, et al.
Oncotarget
|
August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Molecular Cancer Therapeutics
|
April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Journal of Medicinal Chemistry
|
November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing
John C Reader, Thomas P Matthews, Suki Klair, et al.
Page
of 4